A Study to Assess PV-10 Chemoablation of Cancer of the Liver

Inclusion Criteria: * Age 18 years or older, males and females. * Histologically or cytologically confirmed, or clinically diagnosed based on currently accepted standards, cancer metastatic to the liver or HCC that is not amenable at the time of enrollment to resection, transplant or other potentially curative therapy. * At least one Target Lesion determined to be amenable to percutaneous injection by the treating physician. * Target Lesion(s) must have measurable disease, defined as a unidimensionally measurable lesion ≥ 1.0 cm in longest diameter by helical CT; the maximum diameter of Target Lesion(s) shall be ≤ 4.9 cm. * Performance status of Karnofsky scale 60%-100% or ECOG performance scale 0-2. * Life expectancy ≥ 12 weeks. * Hematopoietic Function: WBC ≥ 2,500/mm3; ANC ≥ 1000/mm3; Hemoglobin ≥ 8 g/dL; Platelet count ≥ 50,000/mm3; Coagulation: INR ≤ 1.3. * AST and ALT \< 5 times ULN; ALP \< 5 times ULN; Bilirubin ≤ 1.5 times ULN; Creatinine ≤ 1.5 times ULN and eGFR ≥ 50. * Thyroid Function: Total T3 or free T3, total T4 or free T4 and THS ≤ CTCAE Grade 2 abnormality. * Renal Function: Adequate renal function in the opinion of the Investigator with no clinically significant renal impairment or uncontrolled renal disease. * Cardiovascular Function: Adequate cardiovascular function in the opinion of the Investigator with no clinically significant uncontrolled cardiovascular disease. * Respiratory Function: Adequate respiratory function in the opinion of the Investigator w…